Pricing Log in Create free account

Eupraxia Pharmaceuticals Inc. (EPRX) vs Monopar Therapeutics Inc. (MNPR)

Eupraxia Pharmaceuticals Inc. and Monopar Therapeutics Inc. are both Biotechnology companies. Eupraxia Pharmaceuticals Inc. and Monopar Therapeutics Inc. are of similar size ($469.1M and $447.3M). Across the 9 metrics below, Monopar Therapeutics Inc. leads on 8 and Eupraxia Pharmaceuticals Inc. on 1.

Valuation

Metric EPRX MNPR Biotechnology median
P/E n/m n/m 10.64
P/S n/m n/m 9.59
P/B 4.56 4.55 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales n/m n/m 9.45
Earnings yield (14.34%) (3.11%) (34.69%)
Free cash flow yield (8.38%) (2.05%) (24.02%)

Profitability

Metric EPRX MNPR Biotechnology median
Gross margin — — 65.59%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (117.82%) (19.50%) (51.96%)
Return on assets (64.44%) (18.90%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EPRX MNPR Biotechnology median
Revenue growth (TTM) — — 4.59%
EPS growth (last fiscal year) (35.53%) 54.99% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric EPRX MNPR Biotechnology median
Debt to equity 0.01 0.00 0.00
Current ratio 16.00 33.56 4.86
Net debt to EBITDA 2.11 8.06 1.01

Dividend

Metric EPRX MNPR Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric EPRX MNPR Biotechnology median
Market cap 447.34m 469.11m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack